|
Multimedia
Images, audio, and video related to cancer research
Calendar
Meetings, seminars, and press conferences focused on cancer research
Resources
Information on cancer types, treatment, prevention, and more
 Sponsored by:
The Cancer News Portal is supported by the National Cancer Institute of the National Institutes of Health. Additional information on cancer research, prevention, and treatment is available at www.cancer.gov |
Breaking News
Key: Meeting
Showing releases 276-300 out of 1198. << < 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 > >>
Public Release: 10-Apr-2013
AACR Annual Meeting 2013AACR news: Studies show increasing evidence that androgen drives breast cancer Estrogen and progesterone receptors, and the gene HER2 -- these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: Androgen receptors. Contact: Garth Sundem
Public Release: 10-Apr-2013
AACR Annual Meeting 2013Fox Chase researchers find some lung cancers linked to common virus A common virus known to cause cervical and head and neck cancers may also trigger some cases of lung cancer, according to new research presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Wednesday, April 10. Contact: Diana Quattrone
Public Release: 10-Apr-2013
American Chemical Society's 245th National Meeting & ExpositionGUMBOS technology promises new drugs, electronic devices Mention a breakthrough involving "gumbo" technology, and people think of a new twist on the local dish, the stew that's the quintessence of southern Louisiana cooking. But scientific presentations at a meeting of the world's largest scientific society are focusing on what may be an advance in developing GUMBOS-based materials with far-reaching medical, electronic and other uses. Scientists reported on the materials at the 245th National Meeting & Exposition of the American Chemical Society. Contact: Michael Bernstein
Public Release: 10-Apr-2013
 Science Translational MedicineSignature of circulating breast tumor cells that spread to the brain found Some breast tumor circulating cells in the bloodstream are marked by a constellation of biomarkers that identify them as those destined to seed the brain with a deadly spread of cancer, said researchers led by those at Baylor College of Medicine in a report that appears online in the journal Science Translational Medicine. Contact: Glenna Picton
Public Release: 9-Apr-2013
AACR Annual Meeting 2013Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs An irregularity within many neuroblastoma cells may indicate whether the tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors. 
V Foundation for Cancer Research, Friends for Life Fellowship, Howard Hughes Medical Institute
Contact: Teresa Herbert
Public Release: 9-Apr-2013
AACR Annual Meeting 2013AACR news: Misregulated genes common to tobacco-related cancers offer potential new prognostic tool "We ultimately envision this as a prognostic tool to predict survival rates for people with tobacco-related cancers. Recognizing patients with high expression of these genes could help us predict risk and so match patients with the most appropriate treatments," says a researcher. Contact: Garth Sundem
Public Release: 9-Apr-2013
JAMAAssociation between genetic mutation and risk of death for patients with thyroid cancer Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue. Contact: Vanessa Wasta
Public Release: 9-Apr-2013
AACR Annual Meeting 2013AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer Research from the University of Colorado Cancer Center and the Colorado State University Flint Animal Cancer Center presented at the AACR Annual Meeting 2013 used easily available K9 osteosarcoma samples to discover a novel protein that governs metastasis and chemoresistance in pediatric osteosarcoma. Contact: Garth Sundem
Public Release: 9-Apr-2013
AACR Annual Meeting 2013Omega-3 fatty acids more effective at inhibiting growth of triple-negative breast cancer Omega-3 fatty acids are found in oily fish like sardines and salmon, and also in oils derived from plants like hemp and flax. Previous studies suggest these compounds can negatively affect critical mechanisms in cancer cells, namely those responsible for proliferation and for apoptosis, or programmed cell death. Contact: Diana Quattrone
Public Release: 9-Apr-2013
AACR Annual Meeting 2013Researchers identify critical metabolic alterations in triple-negative breast cancer cells Researchers at Fox Chase Cancer Center have identified a host of small molecules critical to metabolism in cells of triple-negative breast cancer -- one of the least understood groups of breast cancer. These molecules, called metabolites, include key players in energy regulation and lipid synthesis. They could help pave the way for helping researchers differentiate among different forms of the disease and ultimately point to new targets for treatment. Contact: Diana Quattrone
Public Release: 9-Apr-2013
AACR Annual Meeting 2013New technology spots drugs' early impact on cancer A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors, providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013 on Tuesday, April 9. Contact: Diana Quattrone
Public Release: 9-Apr-2013
AACR Annual Meeting 2013AACR news: New target plus new drug equals death of melanoma cells Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them. Contact: Garth Sundem
Public Release: 9-Apr-2013
Proceedings of the National Academy of SciencesNew genetic link found between normal fetal growth and cancer NIH researchers discovered a genetic switch that appears to activate the rapid growth of healthy fetuses and the uncontrolled cell division in cancer. The scientists focused on a growth-promoting gene called IGF2. They found evidence that a protein known as E2F3 activates the IGF2 gene in normal development and in cancer -- in particular, in bladder and metastatic prostate cancers.
NIH/National Institute of Child Health and Human Development
Contact: Alisa Machalek
Public Release: 9-Apr-2013
AACR Annual Meeting 2013Mayo researchers identify gene variations that predict chemotherapy side effects Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found. The study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy, a condition that is hard to predict and often debilitating enough to cause cancer patients to stop their treatment early. Results of the research were presented today at the American Association for Cancer Research Annual Meeting 2013 in Washington, D.C.
National Institutes of Health, American Cancer Society, Richard M. Schulze Family Foundation, and more
Contact: Joe Dangor
Public Release: 9-Apr-2013
AACR Annual Meeting 2013AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize In results presented at the AACR Annual Meeting 2013, researchers from the University of Colorado Cancer Center show that the Six2 homeoprotein, while not involved in primary tumor growth, allows cells to detach from substrates and to survive their transition through the bloodstream to faraway sites of metastasis. Contact: Garth Sundem
Public Release: 9-Apr-2013
AACR Annual Meeting 2013AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors BIND Therapeutics clinical investigators presented Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors. BIND-014 was shown to be generally safe and well-tolerated at the established maximum tolerated dose and showed encouraging signs of anti-tumor activity including one complete response, three partial responses and five patients with stable disease lasting at least four cycles.
BIND Therapeutics
Contact: Kathryn Morris
Public Release: 9-Apr-2013
AACR Annual Meeting 2013UCLA researchers find potential link between auto pollution, some childhood cancers Researchers at UCLA's Fielding School of Public Health, led by Julia Heck, assistant researcher in the department of epidemiology and member of the Jonsson Comprehensive Cancer Center, have found a possible link between exposure to traffic-related air pollution and several childhood cancers in the first study on traffic air pollution and childhood cancers (other than leukemia, lymphomas and brain tumors). Contact: Shaun Mason
Public Release: 9-Apr-2013
New PhytologistReliably higher levels of healthy compound in Beneforte broccoli Field trials and genetic studies have shown that a new variety of broccoli reliably yields higher levels of a health-promoting compound. Broccoli contains a compound called glucoraphanin, which has been shown to promote health by maintaining cardiovascular health and a reduction in the risk of cancer. A long term breeding programme to increase glucoraphanin levels has resulted in the commercial release of Beneforte broccoli. Beneforte was developed by crossing standard broccoli with a wild relative.
Biological Sciences Research Council
Contact: Andrew Chapple
Public Release: 9-Apr-2013
PLOS ONE2-drug combo more effective in treating sarcomas, Moffitt Cancer Center study shows Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors. They report that the drug combination of MK-1775 and gemcitabine resulted in a 70 percent decrease in the tumor volume when compared to receiving one drug or the other. Contact: Kim Polacek
Public Release: 9-Apr-2013
Breast Cancer Research and Treatment25 percent don't complete recommended breast cancer treatment One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.
NIH/National Cancer Institute, NIH/National Institute for Nursing Research, American Cancer Society
Contact: Nicole Fawcett
Public Release: 9-Apr-2013
Journal of Clinical OncologyFirst genetic factor in prostate cancer prognosis identified Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease. Contact: Nuria Noriega
Public Release: 9-Apr-2013
AACR Annual Meeting 2013AACR news: Little molecule makes big difference in bladder cancer metastasis In order to kill, bladder cancer must metastasize, most commonly in the lung -- what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University of Colorado Cancer Center at the AACR Annual Meeting 2013 shows that one big difference is a little molecule known as hsa-miR-146a. Contact: Garth Sundem
Public Release: 9-Apr-2013
AACR Annual Meeting 2013TGen-Scottsdale Healthcare clinical trial results for BIND-014 presented at AACR 2013 The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute and Scottsdale Healthcare, and presented today at the American Association for Cancer Research Annual Meeting 2013. Contact: Steve Yozwiak
Public Release: 9-Apr-2013
AACR Annual Meeting 2013TGen-Scottsdale Healthcare clinical trial finds new class of cancer drugs safe and effective The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute. Early results from the phase I, first in-human study of an RNA interface drug were announced during the American Association for Cancer Research Annual Meeting 2013. Contact: Steve Yozwiak
Public Release: 9-Apr-2013
AACR Annual Meeting 2013AACR news: Rigosertib Phase 1 results lead to disease-focused Phase 2 development "Based on these studies, we are initiating an 80-patient, multi-institutional Phase 2 trial," says a researcher. Contact: Garth Sundem
Showing releases 276-300 out of 1198. << < 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 > >>
|
Search News Releases
|
|||||||||||||||||||||||||
 |
||||
|
|
 |
|